Cord blood market segmentation is one of the most important (and least appreciated) parts of analyzing the cord blood banking industry.
As the first and only market research firm to track the stem cell industry, BioInformant has collected a full decade of historical information on the cord blood industry (2006 to present). This provides both a powerful record if past industry dynamics, as well as a robust platform for making future projections.
After 10 years of market analysis, we have come to the conclusion that most people associate the term “cord blood” with the long-term storage of cord blood and tissue stem cells, a service known as “biobanking.”
However, this interpretation provides an incomplete understanding of cord blood industry opportunities and revenue models.
Proper cord blood industry market segmentation produces five different categories, of which cord blood banking is only one.
Cord Blood Market Segmentation
Nearly every company offering cord blood services now states this sentence or one similar to it:
“Cord blood stems cells can treat nearly 80 diseases, including various cancers, genetic diseases, and blood disorders.”
This sentence is important, because it captures the breadth and depth of treatments that cord blood-derived stem cells can facilitate.
However, there are several different strategies that companies can use to derive revenue from cord blood banking products and services, as shown in the cord blood market segmentation below.